Back

Budget Impact Analysis Of The Introduction Of Ranibizumabs Biosimilar To The Jordanian Joint Procurement System.

2026-01-16 health economics Title + abstract only
View on medRxiv
Show abstract

IntroductionThe adoption of biologic therapies imposes a substantial financial burden on the Jordanian healthcare system. Ranibizumab is prescribed for various retinal disorders, and its associated costs are considerable. The introduction of biosimilars is beneficial in retaining desired clinical parameters while providing cost relief and enhanced access to patients. ObjectiveTo examine the budget impact and expanded access of switching to ranibizumabs biosimilar for the management of retinal d...

Predicted journal destinations